Targeted therapies for patients with germ cell tumors

Bibliography

• Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977;87(3):293-8
   PubMed Web of Science ®Google Scholar
• Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316(23):1435-40
   PubMed Web of Science ®Google Scholar
• Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 2003;97(8):1869-75
   PubMed Web of Science ®Google Scholar
• International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15(2):594-603
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Kollmannsberger C, Metzner B, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003;21(22):4083-91
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007;25(3):247-56
   PubMed Web of Science ®Google Scholar
• EORTC protocol 30974. European Organisation for Research and Treatment of Cancer (EORTC) website. Available from: http://www.eortc.be/protoc/details.asp?protocol=30974 [Last accessed 12 December 2007]
   Google Scholar
• Krege S, Beyer J, Souchon R, et al. European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG). Eur Urol 2008;53:478-96
   Google Scholar
• Krege S, Beyer J, Souchon R, et al. European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG). Eur Urol 2008;53:497-513
   Google Scholar
• Ronnen EA, Kondagunta GV, Bacik J, et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol 2005;23(28):6999-7004
   PubMed Web of Science ®Google Scholar
• Donadio AC, Motzer RJ, Bajorin DF, et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol 2003;21(23):4285-91
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007;357(4):340-8
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007;25(1):85-90
   PubMed Web of Science ®Google Scholar
• Lorch A, Kollmannsberger C, Hartmann JT, et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 2007;25(19):2778-84
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005;23(27):6549-55
   PubMed Web of Science ®Google Scholar
• Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005;16(7):1152-9
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Nichols C, Bokemeyer C. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer 2006;106(6):1217-26
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 2008;19:448-53
   PubMed Web of Science ®Google Scholar
• EORTC protocol 30983. European Organisation for Research and Treatment of Cancer (EORTC) website. Available from: http://www.eortc.be/protoc/details.asp?protocol=30983 [Last accessed 12 December 2007]
   Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
   PubMed Web of Science ®Google Scholar
• Reuter VE. Origins and molecular biology of testicular germ cell tumors. Mod Pathol 2005;18(Suppl 2):S51-60
   PubMed Web of Science ®Google Scholar
• Bomeisl PE, Maclennan GT. Spermatocytic seminoma. J Urol 2007;177(2):734
   PubMed Web of Science ®Google Scholar
• Oosterhuis JW, Looijenga LH. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 2005;5(3):210-22
   PubMed Web of Science ®Google Scholar
• Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet 2006;367(9512):754-65
   PubMed Web of Science ®Google Scholar
• Mostert MC, Verkerk AJ, Van De Pol M, et al. Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults. Oncogene 1998;16(20):2617-27
   PubMed Web of Science ®Google Scholar
• Olie RA, Looijenga LH, Boerrigter L, et al. N- and KRAS mutations in primary testicular germ cell tumors: incidence and possible biological implications. Genes Chromosomes Cancer 1995;12(2):110-6
   PubMed Web of Science ®Google Scholar
• Roelofs H, Mostert MC, Pompe K, et al. Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. Am J Pathol 2000;157(4):1155-66
   PubMed Web of Science ®Google Scholar
• Schmidt BA, Rose A, Steinhoff C, et al. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors. Cancer Res 2001;61(10):4214-21
   PubMed Web of Science ®Google Scholar
• Santagata S, Ligon KL, Hornick JL. Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol 2007;31(6):836-45
   PubMed Web of Science ®Google Scholar
• Olasz J, Mandoky L, Geczi L, et al. Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors. Anticancer Res 2005;25(6B):4319-24
   PubMed Web of Science ®Google Scholar
• Velasco A, Corvalan A, Wistuba II, et al. Mismatch repair expression in testicular cancer predicts recurrence and survival. Int J Cancer 2007;122:1774-7
   Web of Science ®Google Scholar
• Smiraglia DJ, Szymanska J, Kraggerud SM, et al. Distinct epigenetic phenotypes in seminomatous and non-seminomatous testicular germ cell tumors. Oncogene 2002;21(24):3909-16
   PubMed Web of Science ®Google Scholar
• Koul S, Mckiernan JM, Narayan G, et al. Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol Cancer 2004;3:16
   PubMed Web of Science ®Google Scholar
• Manova K, Nocka K, Besmer P, Bachvarova RF. Gonadal expression of c-kit encoded at the W locus of the mouse. Development 1990;110(4):1057-69
   PubMed Web of Science ®Google Scholar
• Rossi P, Albanesi C, Grimaldi P, Geremia R. Expression of the mRNA for the ligand of c-kit in mouse Sertoli cells. Biochem Biophys Res Commun 1991;176(2):910-4
   PubMed Web of Science ®Google Scholar
• Izquierdo MA, Van Der Valk P, Van Ark-Otte J, et al. Differential expression of the c-kit proto-oncogene in germ cell tumours. J Pathol 1995;177(3):253-8
   PubMed Web of Science ®Google Scholar
• Madani A, Kemmer K, Sweeney C, et al. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol 2003;14(6):873-80
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279(5350):577-80
   PubMed Web of Science ®Google Scholar
• Sakuma Y, Sakurai S, Oguni S, et al. Alterations of the c-kit gene in testicular germ cell tumors. Cancer Sci 2003;94(6):486-91
   PubMed Web of Science ®Google Scholar
• Looijenga LH, De Leeuw H, Van Oorschot M, et al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res 2003;63(22):7674-8
   PubMed Web of Science ®Google Scholar
• Biermann K, Göke F, Nettersheim D, et al. c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma. J Pathol 2007;213(3):311-8
   PubMed Web of Science ®Google Scholar
• Coffey J, Linger R, Pugh J, et al. Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes Chromosomes Cancer 2008;47(1):34-42
   PubMed Web of Science ®Google Scholar
• Mcintyre A, Summersgill B, Grygalewicz B, et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 2005;65(18):8085-9
   PubMed Web of Science ®Google Scholar
• Caponigro F, Milano A, Ottaiano A, Iaffaioli RV. Epidermal growth factor receptor as a major anticancer drug target. Expert Opin Ther Targets 2006;10(6):877-88
   PubMed Web of Science ®Google Scholar
• Hechelhammer L, Störkel S, Odermatt B, et al. Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors. Virchows Arch 2003;443(1):28-31
   PubMed Web of Science ®Google Scholar
• Moroni M, Veronese S, Schiavo R, et al. Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors. Clin Cancer Res 2001;7(9):2770-5
   PubMed Web of Science ®Google Scholar
• Mandoky L, Geczi L, Bodrogi I, et al. Expression of HER-2/neu in testicular tumors. Anticancer Res 2003;23(4):3447-51
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Mayer F, Pressler H, et al. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer 2002;95(2):301-8
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis. Ann Rev Med 2006;57:1-18
   PubMed Web of Science ®Google Scholar
• Olivarez D, Ulbright T, Deriese W, et al. Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Res 1994;54(10):2800-2
   PubMed Web of Science ®Google Scholar
• Viglietto G, Romano A, Maglione D, et al. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 1996;13(3):577-87
   PubMed Web of Science ®Google Scholar
• Fukuda S, Shirahama T, Imazono Y, et al. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 1999;85(6):1323-30
   PubMed Web of Science ®Google Scholar
• Adam M, Schmidt D, Wardelmann E, et al. Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. Eur Urol 2003;44(3):329-36
   PubMed Web of Science ®Google Scholar
• Houldsworth J, Korkola JE, Bosl GJ, Chaganti RS. Biology and genetics of adult male germ cell tumors. J Clin Oncol 2006;24(35):5512-8
   PubMed Web of Science ®Google Scholar
• Riou G, Barrois M, Prost S, et al. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol Carcinog 1995;12(3):124-31
   PubMed Web of Science ®Google Scholar
• Schenkman NS, Sesterhenn IA, Washington L, et al. Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors. J Urol 1995;154(2):617-21
   PubMed Web of Science ®Google Scholar
• Houldsworth J, Xiao H, Murty VV, et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 1998;16(18):2345-9
   PubMed Web of Science ®Google Scholar
• Burger H, Nooter K, Boersma AW, et al. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int J Cancer 1999;81(4):620-8
   PubMed Web of Science ®Google Scholar
• Voorhoeve PM, Le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006;124(6):1169-81
   PubMed Web of Science ®Google Scholar
• Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-80
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(26):4293-300
   PubMed Web of Science ®Google Scholar
• Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerging Drugs 2006;11(4):635-50
   PubMedGoogle Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341(21):1565-71
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357(21):2133-42
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249-57
   PubMed Web of Science ®Google Scholar
• Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88(12):1979-86
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar
• Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2(5):471-8
   PubMed Web of Science ®Google Scholar
• Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60(8):2178-89
   PubMed Web of Science ®Google Scholar
• Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6(10):803-12
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19(13):3267-79
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007;357(1):39-51
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Ho L, Ranganathan S, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2003;21(7):1301-6
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Van De Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22(8):1430-8
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99(10):3530-9
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-17
   PubMed Web of Science ®Google Scholar
• Davies M, Hennessy B, Mills GB. Point mutations of protein kinases and individualised cancer therapy. Expert Opin Pharmacother 2006;7(16):2243-61
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40(5):689-95
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42(8):1093-103
   PubMed Web of Science ®Google Scholar
• Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884-96
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hoosen S, Bello CL, Christensen JG. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 2006;15(5):553-61
   PubMed Web of Science ®Google Scholar
• Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105(3):986-93
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965-72
   PubMed Web of Science ®Google Scholar
• Smolewski P. Investigating mammalian target of rapamycin inhibitors for their anticancer properties. Expert Opin Investig Drugs 2006;15(10):1201-27
   PubMed Web of Science ®Google Scholar
• Kaur M, Reed E, Sartor O, et al. Suramin's development: what did we learn? Investig New Drugs 2002;20(2):209-19
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Dmitrovsky E, Miller WH, et al. Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer 1993;72(11):3313-7
   PubMed Web of Science ®Google Scholar
• Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003;22(47):7305-15
   PubMed Web of Science ®Google Scholar
• Moasser MM, Motzer RJ, Khoo KS, et al. All-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer 1995;76(4):680-6
   PubMed Web of Science ®Google Scholar
• Gold EJ, Bosl GJ, Itri LM. Phase II trial of 13-cis-retinoic acid in patients with advanced nonseminomatous germ cell tumors. Cancer Treatment Reports 1984;68(10):1287-8
   PubMedGoogle Scholar
• Kollmannsberger C, Pressler H, Mayer F, et al. Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab. Ann Oncol 1999;10(11):1393-4
   PubMed Web of Science ®Google Scholar
• Beer TM, Tangen CM, Nichols CR, et al. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer 2006;106(12):2624-9
   PubMed Web of Science ®Google Scholar
• Rick O, Braun T, Siegert W, Beyer J. Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer 2006;42(12):1775-9
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Brames MJ, Heinrich MC, et al. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 2006;29(1):12-3
   PubMed Web of Science ®Google Scholar
• Pedersini R, Vattemi E, Mazzoleni G, Graiff C. Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. Lancet Oncol 2007;8(11):1039-40
   PubMed Web of Science ®Google Scholar
• Voigt W, Kegel T, Maher G, et al. Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer. Ann Oncol 2006;17(3):531-3
   PubMed Web of Science ®Google Scholar
• Mego M, Recková M, Sycova-Mila Z, et al. Bevacizumab in a growing teratoma syndrome. Case report. Ann Oncol 2007;18(5):962-3
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Rick O, Derigs HG, et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2002;20(8):2031-7
   PubMed Web of Science ®Google Scholar
• Imatinib mesylate in treating patients with progressive, refractory, or recurrent stage II or stage III testicular or ovarian cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00042952 [Last accessed 12 December 2007]
   Google Scholar
• A Phase II study of Iressa in patients with chemorefractory germ cell tumors expressing EGFR. Available from: http://clinicaltrials.gov/ct2/show/NCT00198159 [Last accessed 12 December 2007]
   Google Scholar
• Phase-II study of SU011248 (sunitinib)in male patients with relapsed or cisplatin-refractory germ cell cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00371553 [Last accessed 12 December 2007]
   Google Scholar
• Sunitinib in treating patients with metastatic germ cell tumors that have relapsed or not responded to treatment. Available from: http://clinicaltrials.gov/ct2/show/NCT00453310 [Last accessed 12 December 2007]
   Google Scholar
• Study of oxaliplatin plus bevacizumab in germ cell tumor patients. Available from: http://clinicaltrials.gov/ct2/show/NCT00393861 [Last accessed 12 December 2007]
   Google Scholar
• Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007;7(5):389-97
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-500
   PubMed Web of Science ®Google Scholar
• Holzbeierlein JM, Sogani PC, Sheinfeld J. Histology and clinical outcomes in patients with bilateral testicular germ cell tumors: the Memorial Sloan Kettering Cancer Center experience 1950 to 2001. J Urol 2003;169(6):2122-5
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ligorio C, Jänne PA, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007;25(16):2248-55
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357(20):2040-8
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25(16):2171-7
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44
   PubMed Web of Science ®Google Scholar
• Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25(30):4743-50
   PubMed Web of Science ®Google Scholar
• Silverman LR, Mufti GJ. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol 2005;2(Suppl 1):S12-23
   Google Scholar
• Fenaux P. Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nat Clin Pract Oncol 2005;2(Suppl 1):S36-44
   PubMedGoogle Scholar
• Rothenberg ML, Carbone DP, Johnson DH. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer 2003;3(4):303-9
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(15):1960-6
   PubMed Web of Science ®Google Scholar
• Kersemaekers AM, Mayer F, Molier M, et al. Role of P53 and MDM2 in treatment response of > human germ cell tumors. J Clin Oncol 2002;20:1551-61
   PubMed Web of Science ®Google Scholar